Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Michael Kallelis to manage Exiqon's new US facility
Exiqon’s US operations will start Q1 2006


Copenhagen, January 4th, 2006 – Exiqon A/S, a leading supplier of high-value gene expression analysis products announced today the appointment of Michael Kallelis as President and General Manager of Exiqon’s new US operations. Mr. Kallelis will have the overall responsibility for launching and operating Exiqon’s US office to be located in the Boston area. A key focus of the new facility will be to expand the sales force to support Exiqon’s successful miRCURY™ microRNA detection products.

Before joining Exiqon, Mr. Kallelis served as a Vice President at Archemix Corp and prior to that as the Executive Vice President and General Manager of Avecia Biotechnology. He also served as Chief Operating Officer and co-founder of Boston BioSystems, a leading GMP manufacturer of oligonucleotides, which was acquired by Avecia in 1999. Over his career, Mr. Kallelis has acquired significant expertise in rapidly building up new businesses from start-up to commercially viable enterprises and has taken a lead management role in mergers and acquisitions.

“Mike possesses the commercial and operational leadership skills which will secure a strong launch of Exiqon’s US operations” said Lars Kongsbak, President and CEO of Exiqon, and continues “Mike also has extensive experience managing technical life science companies and brings the perfect blend of sales, marketing and operations roles that make him a good match for Exiqon’s growing business”.

“During 2005, Exiqon has continued to grow its product sales, quarter to quarter, and a full presence in the US market is an obvious next step” said Jack Johansen, Chairman of the Board of Exiqon. “We are very pleased to have Mike lead this important operation”. Exiqon’s new offices will be located in the Boston area to take full advantage of the life science labor pool and large biotech presence. The new US office plans to begin recruiting its sales staff and administrative support roles immediately. The site will be operational in the first quarter of this year.


About microRNAs and LNATM
MicroRNAs are a novel class of regulatory RNA molecules with surprisingly widespread effects on gene regulation. Although recently identified as a class of molecules, initial studies indicate that microRNAs may regulate as much as 1/3 of all genes in the genome, thus comprising an up until now hidden level of regulation. Interestingly, microRNAs have already been found to play important roles in several types of cancers and in processes involved in cellular differentiation. In the cell, microRNAs are found in form of singlestranded RNA molecules, which are typically 20-25 nucleotides long in their active form. LNAs are a class of nucleotide analogues that bind very strongly to RNA and DNA targets. By including LNAs in detection probes, it is possible to design very specific high-affinity detection assays for small RNA targets like microRNAs, which is not possible using standard DNA-based detection probes.


About Exiqon
Exiqon is a leading supplier of high-value gene expression analysis products for the life sciences, research and drug discovery industries. Exiqon’s rapidly growing product offerings integrate innovative chemistries with web-based software tools to help scientists achieve rapid and reliable results. Exiqon markets its products directly on www.exiqon.com or through distributors and partners its proprietary Locked Nucleic Acids (LNA™) and Anthraquinone (AQ-Link™) technologies through industry leaders. Exiqon is located in the Medicon Valley area of Copenhagen, Denmark. Please visit our web-site at www.exiqon.com.
xx


Publisher Contact Information:

Exiqon A/S
+45 45 65 04 50
lk@exiqon.com

Company profile of Exiqon A/S
Past press releases of Exiqon A/S.

Data


25,894
Tech investments
From our Online Data Service
16,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Jun 29€1.3MSecurity
Jun 28€2.2MDatabase
Jun 28€12.0MMaterials
Jun 28€5.5MBusiness applications
Jun 27€3.0MBiopharmaceuticals
Jun 27€10.0MEnergy related
Jun 27N/AWireless applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.